CRF (human, rat) |
| Katalog-Nr.GC15737 |
Corticotropin-releasing factor human (Human CRF) stimuliert die Synthese und Sekretion von Adrenocorticotropin im Hypophysenvorderlappen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 86784-80-7
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
CRF (human, rat) is an endogenous peptide agonist of the corticotropin-releasing factor (CRF) receptor, with Ki values of 3.3, 42, and 47nM for hCRF1, rCRF2A, and mCRF2B, respectively[1]. CRF (human, rat) is a hypothalamic peptide composed of 41 amino acids that is widely expressed in neurons throughout the mammalian brain and some peripheral tissues (such as the pancreas, stomach, and small intestine)[2]. CRF can stimulate the synthesis and secretion of adrenocorticotropic hormone (ACTH) in the anterior pituitary[3]. CRF can increase the excitability of type II dlBNST neurons by activating the AC-cAMP-PKA pathway, thereby causing pain-induced aversion reactions[4]. The acute central anorectic and hypermetabolic effects of CRF are affected by age and gender[5].
References:
[1] Parra Mercado G K. Papel de*-arrestina2 en la seúalización del receptor para el factor liberador de corticotropina tipo 1 (CRF*)[D]. Tesis (MC)--Centro de Investigación y de Estudios Avanzados del IPN Departamento de Bioquímica., 2015.
[2] De Souza E B, Grigoriadis D E. Corticotropin-releasing factor: Physiology, pharmacology, and role in central nervous system disorders[J]. Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott, Williams and Wilkins, 2002: 91-107.
[3] ABOU‐SAMRA A B, Harwood J P, Catt K J, et al. Mechanisms of action of CRF and other regulators of ACTH release in pituitary corticotrophs[J]. Annals of the New York Academy of Sciences, 1987, 512(1): 67-84.
[4] Kaneko T, Kaneda K, Ohno A, et al. Activation of adenylate cyclase‐cyclic AMP‐protein kinase A signaling by corticotropin‐releasing factor within the dorsolateral bed nucleus of the stria terminalis is involved in pain‐induced aversion[J]. European Journal of Neuroscience, 2016, 44(11): 2914-2924.
[5] Tenk J, Rostás I, Füredi N, et al. Acute central effects of corticotropin-releasing factor (CRF) on energy balance: Effects of age and gender[J]. Peptides, 2016, 85: 63-72.
| Cas No. | 86784-80-7 | SDF | |
| Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/ | ||
| Formula | C208H344N60O63S2 | M.Wt | 4757.45 |
| Löslichkeit | Soluble to 1.10 mg/ml in sterile water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2102 mL | 1.051 mL | 2.102 mL |
| 5 mM | 0.042 mL | 0.2102 mL | 0.4204 mL |
| 10 mM | 0.021 mL | 0.1051 mL | 0.2102 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *